Suzetrigine Became the First New Class of Non-Opioid Pain Medication Approved for Acute Pain in 25 Years. A Pooled Analysis of Five Trials Shows Why It Matters.

Approximately 75% of surgical patients experience postoperative pain, and fewer than half achieve adequate relief with current standard of care. For decades the only genuinely effective option for moderate to severe acute pain has been opioids, drugs that work well but carry addiction potential, respiratory depression risk, and a well-documented path from a single surgical prescription to long-term dependence. Every attempt to find an equally effective non-opioid alternative has come up short, until suzetrigine, also known as VX-548, was approved by the FDA on January 30, 2025, becoming the first new mechanistic class of non-opioid analgesic for acute pain in a quarter century. This systematic review and meta-analysis, conducted by researchers at the All India Institute of Medical Sciences in Rajkot and Mangalagiri, pools every available randomized trial of suzetrigine to give the clearest picture yet of whether the drug actually delivers on that promise.

Bansal and colleagues conducted a PRISMA-guided systematic review and meta-analysis, registered with PROSPERO, searching ClinicalTrials.gov, PubMed, and the Cochrane Central Register of Controlled Trials through June 2025. Five randomized controlled trials met inclusion criteria, four of which were combined in the quantitative meta-analysis, covering bunionectomy as a model of bone pain and abdominoplasty as a model of soft tissue pain. Suzetrigine was compared against both placebo and hydrocodone bitartrate-acetaminophen (HB/APAP), a standard opioid combination, at a loading dose of 100 mg followed by 50 mg every 12 hours. The primary efficacy measures were the time-weighted sum of pain intensity difference over 48 hours (SPID 48) and 24 hours (SPID 24), with secondary measures examining the proportion of patients achieving clinically meaningful pain reductions and a full safety comparison across both comparator groups. Risk of bias was formally assessed using the Cochrane ROB-2 tool.

Across 1,584 participants, suzetrigine produced significantly greater pain relief than placebo, with a standard mean difference of 5.55 for SPID 48 and 5.33 for SPID 24, both highly significant. Patients on suzetrigine were substantially more likely to achieve meaningful pain reduction: the odds of a 30% or greater reduction in pain scores were nearly double that of placebo, and the odds of 50% and 70% reductions were similarly and significantly elevated. When compared directly against the opioid combination HB/APAP, suzetrigine showed no statistically significant difference in overall pain relief, meaning the two were essentially comparable in effectiveness. Where suzetrigine distinguished itself was in safety. The overall incidence of any adverse event was significantly lower with suzetrigine than with either placebo or HB/APAP. Nausea occurred significantly less often with suzetrigine than with the opioid combination, and vomiting occurred significantly less often as well. Serious adverse events were rare and statistically comparable across all three groups.

• —Every trial included in this analysis lasted only 2 to 14 days, evaluating suzetrigine exclusively in acute postoperative settings. None of the available evidence speaks to longer-term use, chronic pain, or whether tolerance could develop with extended dosing.
• —All trials were conducted in two specific surgical models, bunionectomy and abdominoplasty. Efficacy and safety in other types of acute pain, including non-surgical acute pain, trauma, or other surgical procedures, has not yet been established through randomized comparison.
• —Heterogeneity between studies was very high for the primary efficacy outcomes (I² = 99%), meaning the pooled effect size, while statistically significant, should be interpreted with some caution given how much the individual trial results varied from one another.
• —Publication bias could not be formally assessed because fewer than ten studies were available for meta-analysis, which is the standard threshold below which such analyses become statistically unreliable.
• —All five included trials were sponsored by the drug's manufacturer, which is disclosed transparently in each trial but is a standard limitation to weigh when interpreting industry-funded efficacy data.

Suzetrigine represents the first new class of non-opioid analgesic for acute pain approved in 25 years, and this pooled analysis of the available randomized evidence supports the case for why that approval mattered. It relieves pain about as well as a standard opioid, with meaningfully fewer side effects and none of the central nervous system mechanism that drives opioid addiction. The evidence so far comes exclusively from short surgical trials, and whether this profile holds up across broader acute pain settings and longer use remains to be seen. But for a health system that has spent two decades searching for a genuine alternative to opioids for acute pain, this is the most encouraging pooled data that alternative has produced yet.